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Inflammation is a major stimulus for carcinogenesis; however inflammation can also inhibit tumor growth and deplete
malignant cells. The differences between cancer-promoting and cancer-inhibitory inflammation are not clear. We
identified Interferon-c as a major mediator of cancer-inhibitory inflammation that promotes anti-cancer immunity in the
liver and sensitizes malignant hepatocytes for apoptosis.
Inflammation is a critical promoter of
carcinogenesis. Indeed, a characteristic of
most, if not all tumors is a microenviron-
ment of inflammatory cells and mediators
that enables the growth of malignant cells
and their acquisition of the ‘hallmarks of
cancer’.
1 Moreover, chronic inflammation
predisposes to several types of cancer, such
as hepatocellular carcinoma.
2 However,
inflammation has also the capacity to
inhibit carcinogenesis by depleting malig-
nant cells, and even to induce regression
of established tumors.
2,3 Currently, our
knowledge of what makes the difference
between tumor-promoting and tumor-
inhibitory inflammation is rather limited.
To develop more effective anti-tumor
therapies, we need to define key inflam-
matory mediators and pathways that can
turn tumor-promoting inflammation into
anti-cancer immunity.
Hepatocellular carcinoma is a paradigm
for inflammation-induced cancer, since it
develops most frequently on grounds of
chronic liver inflammation, consecutive
tissue damage and compensatory regenera-
tion.
2 An important component of the
tumor-promoting inflammatory infiltrate
are tumor-associated macrophages that
exhibit an M2 phenotype and promote
tissue remodeling and angiogenesis.
2 The
initiation of liver cancer has been linked to
activation of the NFkB pathway in liver
macrophages and the secretion of inter-
leukin-6, which, in turn, stimulates the
STAT3 pathway in hepatocytes and
enables the survival and proliferation of
damaged cells.
4,5 Inflammatory lympho-
cytes can also secrete STAT3-activating
cytokines, such as interleukin-22, that may
further promote liver cancer.
6
However, the common notion that
chronic liver inflammation unequivocally
promotes hepatocarcinogenesis may be an
over-simplification.Indeed, clinicalobserva-
tions suggests that some chronic inflam-
matory liver diseases, such as viral hepatitis,
progress more commonly to liver cancer
than others; e.g., autoimmune hepatitis.
Moreover, we noticed that transgenic mice,
which overexpress interferon-c (IFNc) in
the liver and manifest lifelong liver inflam-
mation with persistent liver damage and
regeneration, are not prone to spontaneous
liver cancer.
7,8 Therefore, we induced
chemical hepatocarcinogenesis inthese mice
byapplicationofdiethylnitrosamine.
8Quite
surprisingly, chemical hepatocarcinogenesis
was suppressed in the IFNc-transgenic mice
despite overt liver injury.
8 Indeed, IFNc-
transgenic mice developed fewer and less
advanced lesions, suggesting that IFNc may
suppress both the initiation and the promo-
tion of liver cancer. The tumor-suppressive
effect of IFNc seemed to be mediated in
part by increasing tumor immune surveil-
lance by lymphocytes, indicated by a strong
infiltration of IFNc-transgenic livers with
CD8 T cells, NKT and NK cells.
8 In
addition, IFNc seemed to prevent carcino-
genesis also by direct effects on damaged or
malignant hepatocytes.
8 IFNc induced a
sustained and non-refractory activation of
the STAT1 pathway in hepatocytes, but
only transient STAT3 activation.
8 This
IFNc-induced activation of the STAT1
pathway was associated with an activation
of the p53 tumor suppressor pathway.
8
Indeed, IFNc induced accumulation of
p53 and sensitized hepatocytes to apoptotic
cell death in response to genotoxic stress.
8
These findings indicate that the carcino-
genic potential of chronic inflammation is
determined by type and composition of its
mediators, most notably the proportion of
IFNc-secreting lymphocytes in chronic
inflammatory tissue infiltrates.
We thus propose that the differences
between tumor-promoting and tumor-
inhibitory liver inflammation may be
explained not only by the degree of
cytotoxic activity of inflammatory cells,
but also by predominance of either
STAT1-activating cytokines, such as
IFNc, or STAT3-activating cytokines,
such as interleukin-6 or interleukin-22
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Do not distribute. (Fig.1). This model is compatible with
the finding that the balance of STAT1 and
STAT3 activation seems to predict the
clinical outcome in cutaneous melanoma.
9
During tumor promotion, the presence
or absence of IFNc further influences
the tumor microenvironment and tissue
remodelling. Indeed, IFNc is known to pro-
mote macrophage polarization toward an
M1 phenotype and to inhibit fibrogenesis,
whereas M2 macrophages, which are
induced by non-IFNc producing lympho-
cytes and malignant hepatocytes, promote
fibrogenesis and angiogenesis. It is con-
ceivable that the presence of IFNc during
tumor promotion may prevent induction
of M2 macrophages. In summary, inflam-
matory infiltrates with high content of
IFNc-secreting lymphocytes, i.e., Th1
cells, CD8 T cells, some NK cells and
some NKT cells, may characterize tumor-
suppressive inflammation, whereas infil-
trates with high content of IFNc
non-producing or interleukin-22 pro-
ducing lymphocytes may characterize
tumor-promoting infiltrates. Therefore,
manipulating the type of chronic inflam-
mation and the composition of tumor-
associated inflammatory infiltrates may
serve the prevention of cancer.
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Figure1. A model of cancer-promoting and cancer-inhibitory liver inflammation. Tumor-suppressive inflammatory liver infiltrates are characterized by
high content of IFNc-secreting lymphocytes (Th1, CD8 T, NK and NKT cells), sustained activation of the STAT1 pathway in hepatocytes, macrophage
polarization toward an M1 phenotype and fibrolysis. In contrast, tumor-promoting liver infiltrates are characterized by high content of IFNc non-
producing or interleukin-22 producing lymphocytes, interleukin-6 secretion by various cell types, macrophages with M2 phenotype, sustained STAT3
activation in hepatocytes, fibrogenesis and angiogenesis.
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